Hansas immunomodulatory enzyme does the job
Sweden’s Hansa Medical AB presented data showing its experimental drug allowed doctors to perform successful kidney transplants in patients with a particularly high risk of organ rejection.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
Entries by Thomas Gabrielczyk
J&J intensifies vaccine endeavour with Bavarian Nordic
/in News/by Thomas GabrielczykJohnson & Johnson has entered a new deal with Danish biotech Bavarian Nordic worth up to US$879m to develop vaccine regimens against hepatitis B and HIV.
GSK cancels 30 preclinical and clinical programmes
/in News/by Thomas GabrielczykUKs biggest pharma firm announced it will save an additional £1bn each year by 2020. 80% of the pharmaceutical R&D pipeline expenses will be directed towards two current (Respiratory and […]
Ablynx adds Sanofi to its list of pharma partners
/in News/by Thomas GabrielczykBelgian nanobody-developer Ablynx NV now also works together with French pharma company Sanofi. The deal is potentially worth 2.4bn but comes with an upfront payment of just 23m. The partners […]
Seventure debuts in Japan with microbiome investment
/in News/by Thomas GabrielczykVenture capitalist Seventure Partners announced that it has participated in a US$13m financing of Japanese biotech company Anaeropharma Science. The investment is made from Seventures Health for Life Capital investment […]